Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Rankin Aubrey	2. Issuer Name and Ticker or Trading Symbol Revance Therapeutics, Inc. [ RVNC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President, Innovation & Tech
(Last)          (First)          (Middle) C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 2000	3. Date of Earliest Transaction (MM/DD/YYYY) 8/15/2021
(Street) NASHVILLE, TN 37203 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	8/15/2021		F		4949 (1)	D	$26.02 (2)	74827	D
Common Stock	8/16/2021		S(3)		9364	D	$26.3412 (4)	65463	D
Common Stock								321611	I	Aubrey and Luanne Rankin Revocable Living Trust Dated July 1, 2009 (5)
Common Stock								154302	I	The Rankin Irrevocable Trust (6)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	Represents the number of shares withheld by and surrendered to the Issuer on August 15, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 57,251 shares. The RSA vests in three equal annual installments from August 15, 2020, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Inducement Plan (the "Plan")) on each vesting date.
(2)	The fair market value was determined on August 13, 2021 pursuant to the Plan.
(3)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Rankin.
(4)	The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $26.71. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
(5)	These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
(6)	These shares are held by The Rankin Irrevocable Trust, of which the children of Mr. Rankin are beneficiaries.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Rankin Aubrey C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, SUITE 2000 NASHVILLE, TN 37203	X		President, Innovation & Tech

Signatures
/s/ Dwight Moxie, Attorney-in-Fact		8/17/2021
**Signature of Reporting Person		Date